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Abstract. We have studied the distribution of the plas- 
minogen activator inhibitor type 1 (PAI-1) in cultures 
of confluent human umbilical vein endothelial cells. 
Plasminogen activator inhibitor activity measured by 
the t~5I-fibrin plate assay was detected in the cytosol 
(2.85  +  0.16 U),  100,000 g particulate fraction (1.26 
-t- 0.30 U), and in the growth substratum (9.82  +  1.80 
U). Characterization  of the protein responsible for this 
activity by reverse fibrin autography,  immunoprecipita- 
tion, and immunoblotting demonstrated that it had an 
Mr of 46,000 and was antigenically related to PAI-I. 
Only the active form of the inhibitor was found in all 
three fractions. Inhibitor in the cytosol and particulate 
fraction converted to the latent form during 37~  incu- 
bation while the substratum inhibitor remained fully 
active.  Extracellular PAI-I  was detected in the growth 
substratum before its appearance in conditioned medi- 
um and represented the major protein deposited be- 
neath the cells. The inhibitor was only transiently 
localized in the substratum,  disappearing within 6 h 
and concomitantly appearing in the culture medium. 
Incubation of isolated metabolically labeled substratum 
with tissue plasminogen activator (tPA)  resulted in the 
appearance and release of an immunologicalIy related 
inactive 44,000 Mr form as well as the tPA-PAI-1  com- 
plex (110,000 Mr).  PAI-1 was also converted into its 
44,000-Mr form and released by treatment of the sub- 
stratum with human leukocyte elastase. The rapid 
deposition and predominance of PAI-1 in the underly- 
ing compartment of endothelial cells may explain how 
the basement membrane is protected from proteolytic 
degradation by plasmin-generating  enzymes. 
C  U LTU  RED human endothelial cells produce and release 
an inhibitor of plasminogen  activator (PAI-1)  I that is 
found in a variety of other cell lines as well as plasma 
and platelets  (1, 4-6,  8,  9,  15,  19, 24,  32).  This inhibitor 
is both immtmochemically  and biochemically distinct  from 
other  known plasminogen  activator  inhibitors  (7,  16,  30, 
33-35) and is considered to be a primary inhibitor  of both 
tissue plasminogen  activator (tPA) and urokinase plasmino- 
gen activator (uPA). The inhibitor is found in the conditioned 
medium of various cell lines in two forms: an active form, 
which inhibits tPA and uPA, and a latent form, which in its 
native state has no inhibitor  activity but which can be con- 
verted to an active form by treatment with protein denatur- 
ents such as SDS (1, 12, 20, 31, 32). Greater than 98% of the 
extracellular  PAl-1 of most cells tested is present in the latent 
form (1, 20, 23), although a melanoma cell line has recently 
been described in which the active form of this inhibitor 
predominates in the culture medium (36).  In contrast, our 
studies using human endothelial cells have demonstrated  that 
all  of the intracellular  inhibitor  activity was in the active 
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1. Abbreviations used in this paper: PAl-l, plasminogen activator inhibitor 
type 1; tPA, tissue plasminogen activator; uPA, urokinase plasminogen acti- 
valor. 
form (20). Moreover, during incubation at 37~  the intracel- 
lular inhibitor activity declined but could be regenerated  by 
treatment with SDS, suggesting that conversion to the latent 
form was taking  place during  incubation  (20).  Thus it has 
been suggested that the PAId is synthesized as an active in- 
hibitor but converts to the latent form during or after release 
from the cell. 
It has been reported that the PAId inhibitor  is deposited 
beneath human lung fibroblasts  (18) and fibrosarcoma cells 
(29) as well as secreted into the culture medium.  We have 
investigated  whether the PAI-1 is also associated with the 
growth substratum  and/or other cell components of endo- 
thelial cells, whether it is active or latent,  and whether it is 
stabilized in the active form. We report here that PAI-1 is as- 
sociated with the membrane-containing  particulate  fraction 
and growth substratum of endothelial  cells,  as well as the 
cytosol, and that in all three cases the inhibitor is present in 
the active form. 
Materials and Methods 
Cell Culture 
Endothelial cells were isolated from human umbilical cord veins as previ- 
ously described (22) and were cultured on 12-well tissue culture dishes or 
T-75 culture flasks coated with 20 mg/ml calfskin gelatin (Eastman Chemi- 
cal Products,  Rochester,  NY). Cells were grown to confluence in RPMI- 
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FBS (Irvine Scientific, Irvine, CA), 200 U/ml penicillin, and 200 Ixg/mi 
streptomycin. Primary or secondary cell cultures were used in this study. 
Second passaged cells were grown in 50 ttg/ml endothelial cell growth fac- 
tor (Collaborative Research, Waltham, MA) and 90 gg/mi heparin (Sigma 
Chemical Co.,  St.  Louis,  MO).  Cell density at  confluence was ,o6  ￿ 
10~/cm  2. All experiments were performed on cultures 1-3 d after the cells 
reached confluence. 
Fractionation of  CeUs and Isolation of 
Growth Substratum 
Endothelial cell cultures were washed twice with cold Mg  ++- and Ca  ++- 
free Dulbelcco's PBS and the cells were removed either intact or by deter- 
gent extraction. To remove the cells intact (13, 27), cultures were washed 
twice with 0.1% EDTA and then treated with 0.2 M urea (Bethesda Research 
Laboratories, Bethesda, MD)  -0.1%  EDTA in PBS. The cultures were 
placed on a rotator and incubated for 10 rain at room temperature. The flask 
was hit sharply on a hard surface until the ceils detached. The wells or flask 
were washed two more times with the EDTA-urea-PBS solution and the 
surface monitored visually to insure that all cells were removed. Cell viabil- 
ity as determined by trypan blue staining was 85 % after treatment. Alterna- 
tively, cells were removed by extraction with Na deoxycholate as described 
(11). Briefly, cultures were exposed to 0.5 % Na deoxycholate in 0.01 M Tris- 
HCI, pH 8.0, 0.15 M NaCi three times for 10 rain each at 4~  followed by 
three washes in 2 mM Tris-HC1,  pH 8.0. Extraction solutions contained 
1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM N-ethylmaleimide, 
10 mM EDTA, and loG U/ml aprotinin. Substratum was removed from the 
plastic dish by adding 0.5% SDS in PBS (0.4 ml in a T-75 flask or 400 gl 
per well in a  12-well dish) and scraping with a rubber policeman. 
Cells to be fractionated into soluble and particulate fractions after release 
by urea-EDTA-PBS were washed twice in PBS, suspended in 0.01 M Tris- 
HC1, pH 7.2, 0.015 M NaCI, and allowed to swell for 10 rain at 4~  Cells 
were homogenized with a Dounce homogenizer until no intact cells could 
be detected visually.  The homogenate was cleared of large membrane frag- 
ments and nuclei by centrifugation at 600 g for l0 rain twice. The particulate 
fraction was pelleted by centrifugation at 100,OG0 g for 15 rain in an Airfuge 
(25 psi; Beckman Instruments, Inc., Palo Alto, CA) or through a 5% su- 
crose cushion for 60 rain in a rotor (SW 50.1; Beckman Instruments, Inc.). 
The pellet was then washed with PBS and recentrifuged. Samples to be as- 
sayed for inhibitor activity were prepared in the absence of protease inhibi- 
tors, while samples used in immunoblot experiments contained the inhibi- 
tors listed above. 
[3SS]methioulne labeling was performed by washing cultures twice with 
methionine-free DME (Irvine Scientific) and by adding the same medium 
containing 50 gCi/mi L-[35S]methionine (1320 Ci/mmol; Amersham Corp., 
Arlington Heights, IL) for the times indicated. 
Preparation of  Antibodies to PAIl 
Polyclonal antibodies were prepared from purified human PAId  isolated 
from human endothelial cell-conditioned medium by immunoaifinity chro- 
matography on a PAIl monoclonal antibody-agarose column. Monoclonal 
antibody (250 gg; Monozyme, Lyngby, Denmark) to PAId was coupled to 
1 ml Afligel-10 (BioRad Laboratories, Richmond, CA), the gel equilibrated 
in PBS, and 24-h conditioned medium passed through the column twice. 
The column was washed with 5 column vol of 1.5 M NaC1, 0.1 M sodium 
phosphate, pH 7.2,  reequilibrated in PBS, and the inhibitor eluted with 
0.1 M glycine-HC1, pH 2.5.  The eluate was immediately neutralized with 
1 M Tris-HC1, pH 8.0. The fractions containing PAI-1 activity were pooled, 
dialyzed against PBS, and concentrated by lyophilization. The sample was 
further purified by molecular exclusion chromatography on a  1  ￿  40-era 
P30 column (BioRad Laboratories) in 0.05 M sodium phosphate, pH 7.2, 
0.25 M NaCI. The product migrated as a single band on 9% SDS polyacryl- 
amide gels and contained inhibitor activity as demonstrated by reverse fibrin 
autograph),. 
Antisera against purified PAI-I was raised in rabbits by subcutaneous in- 
jection of 50 gg PAId in PBS emulsified in Freund's complete adjuvant. 
BOoster injections of 50 gg were given at 2-wk intervals, and serum col- 
lected 1 wk after the third booster. The IgG fractions were isolated by chro- 
matography on a protein A-Sepharose column and dialyzed against PBS. 
Enzyme Treatment of  Isolated Substratum 
[35S]methionine-labeled  substratum isolated by urea-EDTA was treated 
with l0 ttg/rnl collagenase (40 U/~tg; Calbiochem-Behring Corp., La Jolla, 
CA) in 50 mM Tris-HC1,  pH 7.2,  10 mM Ca acetate,  10 U  heparinase 
(1,OG0-2,OG0 U/mg;  Sigma  Chemical  Co.)  in  PBS,  0.05  U/mi  chon- 
droitinase ABC (Sigma Chemical Co.) in 40 mM Tris-HCl, pH 8.0, 80 mM 
NaCI, or 0.2 M hcparin for 3 h at 37~  tPA diluted into PBS containing 
0.01% Tween 80 was added in increasing concentrations up to 1.25 ttg,/ml 
for 15 rain. Human leukocyte elastase (10 I~g/mi, 1,0OG U/rag; provided by 
Dr. E. Plow, La Jolla, CA) treatment was for 15 rain at 37~  after which 
2.5 mM elastatinul (an elastase inhibitor; Calbiochem-Behring Corp.) was 
added. After treatment the level of PAI-1 in the substratum and supernatant 
was analyzed by SDS-PAGE and autoradiography, and, when necessary, by 
laser densitometry. 
Assay of  Fibrinolytic Activity and Inhibitor Activity 
Fibrinolytic activity was assayed on  t25I-fibrin plates  as previously de- 
scribed (21). PAId activity was measured by adding increasing volumes of 
sample to a standard amount of tPA and measuring residual tPA activity on 
~25I-fibrin plates. Human tPA was a gift from Dr. D. Collen (University of 
Leuven, Leuven, Belgium) and had a specific activity of  272,000 IU/mg pro- 
tein. Percent residual activity versus sample volume was plotted on a linear 
graph and the number of inhibitor units was calculated from the volume of 
sample giving 50% inhibition oftPA activity.  1 U of inhibitor activity is that 
neutralizing 1 IU of tPA activity. 
Inhibitor samples to be assayed were prepared as follows (20). To mea- 
sure the effect  of  SDS on inhibitor activity in membrane and cytosol isolates, 
the samples were made 0.2%  SDS and the mixture incubated at 37~  for 
l0 min. The samples were made 2% Triton X-loG and tPA added. Samples 
not treated with SDS were made 2 % with Triton X-loG only. Substratum, 
which was removed from the plastic surface with 0.5%  SDS, was also 
treated with 2% Triton X-loG and diluted five times in the same detergent. 
The presence of SDS and Triton X-100 had no effect on tPA activity. 
SDS-PAGE and Reverse Fibrin Autography 
SDS-PAGE was performed by the method of Laemmli (17) with resolving 
gels of 5-15% and stacking gels of 4%. Molecular mass standards included 
myosin (200,000),  ~galactosidase (116,000), phosphorylase B  (92,500), 
BSA (66,000),  ovaibumin (45,000),  carbonic anhydrase (31,000),  and soy- 
bean trypsin inhibitor (21,500).  Samples were boiled in 1% SDS in the pres- 
ence or absence of 5%  13-mercaptoethanol  before electrophoresis. 
Gels to be used for reverse fibrin autography were soaked in 5% Triton 
X-10G for 90 rain, dried with a paper towel, and placed on a reverse fibrin 
autograph containing  I%  agarose, 0.057  NIH  U/ml thrombin, 2  mg/ml 
fibrinogen, 27 mg/mi plasminogen, 1% Triton X-loG, and 0.56 IU/ml tPA. 
The agarose gel was prepared as previously described (10). Complete lysis 
occurred in "o3 h. 
Gels to be analyzed by autoradiofluorography were stained with 0.1% 
Coomassie Brilliant Blue R-250 and 50%  TCA, destained in 10%  acetic 
acid, and then treated with autoradiography enhancer (EN3HANCE; New 
England Nuclear, Boston, MA). 
Immunoblotting and Immunoprecipitation 
After electrophoresis, the samples in the gel were electrophoretically trans- 
ferred onto  a  10  x  15-cm  sheet of nitrocellulose (Trans-Blot;  BioRad 
Laboratories,  Richmond, VA).  Transfer buffer contained 25  mM  Tris- 
glycine, pH 8.3, and 20% methanol; transfer was for 3 h at 3~  at 0.25 A 
and 80 V. After transfer the portion of the nitroceUulose sheet containing 
the standards was removed and stained with 0.1%  Amido black in 45% 
methanol and  10%  acetic acid.  The remaining portion was exposed to a 
polyclonal antibody to human PAI-1 (10 ttg/ml) as described (3,  14). The 
presence of  antibody to the inhibitor was detected by the addition of affinity- 
purified goat anti-rabbit IgG (Zymed, South San Francisco, CA) labeled 
with mI (Amersham Corp.).  Labeling was done with the chloramine T 
method (25)  and 50 gCi of the labeled antibody was used per transfer. 
To prepare samples for immunoprecipitation studies, substratum was re- 
moved from the flask with 500 ttl 0.1% SDS and made 0.5% Triton X-100. 
A  1:10 dilution of anti-PAid or nonimmune rabbit serum at the same con- 
centration was added to samples containing 1% BSA (fraction V), 0.2 M 
NaCI, 1 mM PMSF, and 50 mM Tris-HCl, pH 8.0. Samples were incubated 
for 4 h at room temperature, precipitated with protein A-scpharose (Sigma 
Chemical Co.), and analyzed by SDS-PAGE as previously described (19). 
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Cell Cultures 
Compartment  Inhibitor activity 
U* 
Cytosol  2.85 + 0.16 
100,000 g pellet  1.26 + 0.30 
Matrix (urea)  9.82 +  1.80 
Cell fractions were prepared by removing the cells from a T-75 flask with the 
EDTA-urea-PBS treatment described in Materials and Methods,  followed by 
homogenization in 0.411 M Tris-HC1, pH 7.2, 0.015 M NaCI and centrifugation 
at 100,000 g. The substratum was removed with 0.5%  SDS, made 2% Triton 
X-100, and diluted 1:5 in 2% Triton X-100-PBS,  Inhibitor activity was deter- 
mined by the  J~I-fibrin plate method described  in Materials and Methods. 
* Total  inhibitor units  in each  fraction from one T-75 flask (5  ￿  I0  ~ cells). 
Results 
PAI-1 Activity in Endothelial Cells 
The cytosol, membrane-containing particulate fraction, and 
growth substratum of endothelial cell cultures were assayed 
for PAI-1 activity by the ~zsI-fibrin plate method (Table I). 
Cells released from the substratum by urea-EI~A treatment 
contained ,,,70% of the inhibitor activity in the soluble por- 
tion of  the cell homogenate; the remaining activity was pres- 
ent in  the membrane-containing fraction.  The substratum 
from these cultures deposited by 24-h after confluence con- 
tained more than twice as much activity as the total cell- 
associated material (Table I). To insure that the substratum- 
associated  inhibitor activity was  not a  contaminant  from 
residual plasma membrane fragments remaining on the sub- 
stratum  after urea-EDTA treatment,  substratum  was  also 
prepared using the Na deoxycholate-hypotonic  buffer proce- 
dure (11) and inhibitor activity measured.  [35S]methionine- 
labeled substratum isolated by either procedure showed band 
patterns that were identical with respect to both band number 
and intensity as determined by laser densitometry after SDS- 
PAGE and autoradiofluorography (data not shown). Inhibitor 
Figure L  Reverse fibrin autography and  immunoblotting of en- 
dothelial cell cytosol, 100,000  g pellet, and substratum. Endothelial 
cell cultures were fractionated as described in Materials and Meth- 
ods and reduced samples ofcytosol, 100,000  g pellet (prepared from 
4  x  106 cells), and substratum (one-fifth of the matrix produced 
by 4  x  10  ~ cells 24 h postconfluence) were fractionated by SDS- 
PAGE on 5-15  % gels. (A) PAI-1 was localized by immunoblotting 
with polyclonal antibody to PAId isolated from human endothelial 
cells. (Lane 1) substratum; (lane 2) eytosol; (lane 3) 100,000  g pel- 
let;  (lane  4)  conditioned  medium  (200  ~tl  2,1  h  conditioned 
medium);  (lane 5)  substratum immunoblotted with  nonimmune 
IgG. (B) Gels were analyzed for inhibitor activity by reverse fibrin 
autography. (Lane 1) substratum; (lane 2) 100,000  g pellet; (lane 3) 
cytosol. Mr markers (xl0  -s) are shown at right. 
Table II. Release of  PAl-1 from Endothelial Cell Membrane 
Treatment  Pellet  Supernatant 
%  % 
None  100  -  * 
3 M KC!  97  -* 
10 mM EDTA  107  -* 
6 M guanidine HCI  -*  91 
5  mM Mg2+-Ca  2+  104  -* 
0.5% Triton X-100  -*  79 
0.5 % Na deoxycholate  -*  77 
0.1 M Na carbonate, pH 11.5  55 
Cells  were released  from the  flask by urea-EDTA-PBS and the  membrane 
fraction prepared  by homogenization as described  in Materials and Methods. 
The membrane prepared from one flask of cells was treated with one of the re- 
agents for 30 rain at 23~  (KCI, EDTA, guanidine-HCl,  and divalent cations) 
or 15 min at 4~  (Triton X-100, Na deoxycholate,  Na carbonate). After treat- 
ment the membrane was pelleted by eentrifugation at 100,000 g. Supernatants 
were dialyzed against PBS and the pellets extracted  into 0.5%  Triton  X-100 
in PBS. Inhibitor activity was determined  by the  ~2sI-fibrin plate method and 
the number of inhibitor units in each case compared with control samples treat- 
ed with PBS alone. 
* Undetectable by the assay used. 
activity was also detected in Na deoxycholate-prepared sub- 
stratum and was at similar levels in both samples. Inhibitor 
activity was also deposited beneath cells cultured directly 
onto plastic, as opposed to the gelatin layer normally used. 
SDS-PAGE and reverse fibrin autography of the substra- 
tum, cytosol, and particulate samples showed all inhibitor 
activities were present at an identical position on the gel cor- 
responding to 46,000 Mr (Fig.  1). Immunoblotting of these 
samples and conditioned medium with a polyclonal antibody 
against PAI-1 demonstrated the presence of the PAI-I  at the 
same position as the lysis-resistant zones. A second lighter 
band appearing at 60,000 Mf also appeared in the nonim- 
mune IgG controls. 
The effect of various chemical treatments on the associa- 
tion of the inhibitor with the membrane-containing fraction 
and isolated substratum was determined (Table II). The as- 
sociation  between  inhibitor  and  cell  membrane  was  not 
affected by 3  M  KCI,  10 mM EDTA, or divalent cations. 
However, Triton X-100, Na deoxycholate, guanidine-HCl, or 
0.1 M sodium carbonate, pH 11.5, did remove all detectable 
activity.  To determine whether these  same  treatments  af- 
fected substratum PAI-1, cultures were labeled with [35S]me- 
thionine, the substratum isolated, treated, and the substra- 
tum analyzed with the corresponding supernatant samples 
for the level of PAl-1  by SDS-PAGE and autoradiography. 
Except for guanidine HCI, which at the concentration used 
removed all of the proteins from the substratum, none of the 
treatments had a significant effect on the association between 
the inhibitor and the substratum (data not shown).  We did 
find that acid treatment with 0.1 M glycine-HCl, pH 2.5, re- 
moved all of the labeled inhibitor within 1 rain without de- 
tectably effecting the other proteins, although only 50% of 
the inhibitor activity remained after dissociation from the 
substratum by this procedure. Isolated substratum was also 
treated with collagenase, chondroitinase ABC, heparin, or 
heparinase to determine whether the inhibitor was associated 
with a specific component of the substratum. None of the en- 
zymes  tested  altered  the  relative  molecular  mass  or  the 
amount of PAl-1 in the substratum. 
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substratum and conditioned medium. Endothelial cell cultures were 
grown to confluence and labeled with 50 ttCi/ml  [35S]methionine 
for increasing periods of time. The cells were removed by urea- 
EDTA treatment  as described  in Materials  and Methods  and the 
substratum extracted with 400 ttl 0.5%  SDS. Samples to be used 
for immunoprecipitation were extracted with 0.1% SDS, made 1% 
Triton X-100, and treated with rabbit antiserum against human PAI-1 
as described in Materials and Methods. All samples were fraction- 
ated under reducing conditions by SDS-PAGE on 5-15 % gels fol- 
lowed by autoradiofluorography, aPAI, immune  serum;  lanes M, 
substratum;  lanes S, conditioned medium. 
Deposition of Turnover of  Substratum-associated 
Inhibitor 
Endothelial cell cultures were labeled with [35S]methionine 
for increasing amounts of time and the appearance of PAId 
in the substratum and conditioned medium proteins was fol- 
lowed by SDS-PAGE and autoradiography (Fig. 2).  Within 
30 min after label addition two proteins having an apparent 
Mr of 46,000 had been deposited into the substratum (lanes 
M). Both of these proteins were first detected in the condi- 
tioned medium (lanes S) at 60 min. Immunoprecipitation of 
a  30-min substratum sample with anti-PAid  indicated that 
the slower migrating band was PAId. Immunoprecipitation 
of 60-min conditioned medium gave identical results. PAId 
was increased rapidly and by 2 h composed the major com- 
ponent of the growth substratum and were also prominent in 
the conditioned medium. 
Pulse-chase  experiments  were  performed  to  determine 
the  turnover  rate  of the  inhibitor  in  relation  to  the  other 
substratum-associated proteins.  Cultures  were labeled  for 
Figure  3. Pulse-chase analysis 
of substratum-associated PAI- 
l. Confluent cultures of endo- 
thelial cells were labeled with 
50  ttCi/ml  [35S]methionine 
for 2 h, washed free of label, 
and  then  incubated  in  label- 
free medium for 2, 4, or 6 h. 
Cells were removed by urea- 
EDTA treatment and the sub- 
stratum  (A)  extracted  with 
400  gl 0.5%  SDS, of which 
200  ttl  was  analyzed  under 
reducing  conditions  with the 
corresponding  chase medium 
(B) on 5-15% SDS gels and 
autoradiofluorography. 
Figure 4. Effect of tPA on iso- 
lated substratum. [35S]methio- 
nine-labeled  substratum  pre- 
pared as described in Materials 
and  Methods  was  incubated 
with  1.25 I~g/ml  tPA for 5 or 
15  rain  and  the  substratum 
and supernatant samples were 
analyzed  by  5-15%  SDS- 
PAGE under nonreducing con- 
ditions. (Lane 1) control sub- 
stratum;  (lane  2)  substratum 
treated  with  tPA  for 5  min; 
(lane 3) supernatant from lane 
2; (lane 4) substratum treated with tPA for 15 min; (lane 5) super- 
natant from lane 4; (lane 6) supernatant immunoprecipitated with 
PAI-1 antibodies as described  in Materials  and Methods. 
2 h,  washed,  and  incubated with medium free of radiola- 
beled methionine for 2, 4, and 6 h (Fig. 3). Analysis of the 
substratum (Fig. 3 A) and chase medium (Fig. 3 B) by SDS- 
PAGE showed a decline in the PAId associated with the cul- 
ture vessel surface and a simultaneous increase of the inhibi- 
tor in the conditioned medium. The transfer of inhibitor to 
the medium was almost complete by 6  h.  No other bands 
were significantly effected during the chase period. 
Effect of  tPA and Elastase on Isolated ECM 
To determine whether the  substratum-bound inhibitor was 
susceptible to complex formation with tPA, increasing con- 
centrations oftPA were added to radiolabeled substratum and 
the results analyzed by SDS-PAGE (Fig. 4). No change in the 
inhibitor band was observed when up to 500 ng/ml tPA was 
added (data not shown).  However, after a 5-rain incubation 
with  1.25  ~tg/ml tPA the 46,000-Mr inhibitor band was re- 
duced and two additional  bands at  110,000 and 44,000  Mr 
appeared on the substratum (lane 2) and in the supernatant 
(lane 3).  After 15 rain only a fraction of the 46,000-Mr in- 
hibitor band remained on the substratum (lane 4) while the 
110,000- and 44,000-Mr bands were found only in the super- 
natant (lane 5). Lmmunoprecipitation of PAId from the su- 
pernatant of tPA-treated  substratum demonstrated that  the 
44,000-  and the  ll0,000-Mr bands contained the  inhibitor. 
The inhibitor was not affected by tPA treated with diisopro- 
pylfluorophosphate, indicating that the changes were active 
site dependent.  The  addition  of trasylol did  not  alter the 
results, thereby excluding the possibility that plasmin gener- 
ated from contaminating serum plasminogen was responsi- 
ble for the changes. Thus, the addition of tPA to the isolated 
substratum resulted in tPA-PAI-I complex formation or con- 
version of the inhibitor to a faster migrating form with an ap- 
parent Mr of 44,000 followed by release into the supernatant. 
Elastase, which is a major fibrinolytic protease of leuko- 
cytes (28), also had a significant effect on the inhibitor (Fig. 
5). Within 30 min after elastase addition (4  x  10  -7 M) sev- 
eral of the bands present in control samples (lane 1 M) had 
disappeared.  Most  obvious was  the  disappearance  of the 
band  at  the  top  of the  gel  migrating  at  the  position  of 
fibronectin and the PAId 46,000-Mr band (lane 3 M). Con- 
comimnt with these changes was the appearance of two bands 
in the supernatant, one at 'x,30,000  Mr (the single band be- 
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fluent cultures of endothelial cells were labeled with [35S]methio- 
nine for 4 h and the substratum isolated by urea-EDTA.  Elastase 
(10 lxg/ml) or tPA (1.25 gg/ml) were added for 15 min at 3"/~  and 
the substratum removed with 0.4 ml 0.5% SDS and analyzed under 
nonreducing conditions on SDS gels. Immunoprecipitation experi- 
ments were performed  as described  in Materials and Methods. 
(Lanes 1 ) control substratum; (lanes 2) tPA treated; (lanes 3) elas- 
tase treated; (lanes 4) elastase treated in the presence of 5 Ixg/ml 
anti-tPA antibodies; 0aries 5) immunoprecipitation  with anti-PAI-1 
antibodies. S, supernatant; M, substratum. 
tween the tracker dye and PAl-l) and a second at 44,000 Mr 
(lane 3  S).  The latter band represented PAl-1 as  demon- 
strated by immunoprecipitation with anti-PAI-1  antibodies 
(lane 5 S). Elastase treated with afffinity-purified  antibodies 
to tPA had an identical effect, eliminating the possibility that 
contaminating tPA was responsible (lane 4). 
Previous reports have demonstrated that the decline in the 
apparent relative molecular mass of PAl-1 that occurs during 
incubation with tPA also results in an irreversible loss of in- 
hibitor activity, i.e., PAl-1 that has no anti-tPA activity even 
after treatment with denaturants (26). To determine whether 
tPA and elastase-modified PAl-1 were also affected in this 
manner, isolated substratum was treated under the conditions 
described above and the resulting substratum and superna- 
tant analyzed for activity by reverse fibrin autography.  In 
both cases no lysis-resistant zones were observed in the lanes 
containing treated samples,  indicating that the products of 
tPA and elastase treatment were inactive (data not shown). 
Activity State and Stabilization of the Inhibitor 
The effect of SDS  treatment on the  100,000 g  pellet and 
cytosol-associated inhibitor activity was determined (Table 
IID. No significant change in the amount of inhibitor activity 
was observed after SDS treatment in either case, indicating 
that neither the particulate nor cytosol fractions contained 
detectable  latent  inhibitor.  Incubation  of the  membrane- 
containing fraction and cytosol at 37~  resulted in similar 
loss of activity after 3 h to ,~,40% of that observed in control 
samples. In both cases, <90 % of the original activity was re- 
stored by SDS treatment. Thus, the association of the inhibi- 
tor with particulate components did not alter the decline in 
inhibitor activity (20). 
In contrast, no effect on substratum-bound inhibitor activ- 
ity was observed after long-term incubation at  37~  En- 
dothelial ceils were removed from [35S]methionine-labeled 
substratum by Na deoxycholate-hypotonic  buffer extraction, 
the substratum washed, and the tissue culture dish incubated 
Table IlL Effect of  37~  Incubation and SDS on PAl-1 
Inhibitor activity 
Treatment  -SDS  +SDS  -SDS  +SDS 
U  % control 
Cytosol  2.45  2.60  100  100 
Cytosol at 37~  (3 h)  0.96  2.58  39  99 
Particulate fraction  0.30  0.27  100  100 
Particulate fraction at 37~  (3 h)  0.12  0.25  42  93 
Cytosol and membrane were prepared from cells released by EDTA-urea and 
homogenized as described  in Materials and Methods.  Samples were assayed 
for inhibitor activity by the  ~25I-fibrin plate method after  incubation at 370C 
for 3 h and compared with samples leR at 4"C. SDS treatment was with 0.2% 
SDS for 10 min followed by the addition of Triton X-100 to a final concentra- 
tion of 2%. Cytosol was diluted threefold in 2% Triton X-100 and membrane 
samples were assayed neat.  Values are  the average  of at least two determi- 
nations. 
at 37~  for up to 6 h. tPA was then added to the substratum 
and the shift of  the inhibitor to complex or to the smaller rela- 
tive molecular mass  species was followed. This treatment 
resulted in the complete removal of PAl-1 from the substra- 
tum  and  the  appearance  of both  110,000- and  44,000-Mr 
bands in the supernatant in a  manner identical to that ob- 
served after tPA addition immediately following cell removal 
(Fig. 4). Because tPA has no affect on the latent form of PAI- 
l, the inhibitor must have remained in the active form during 
the incubation period even though cytosol or  membrane- 
bound inhibitor reverted to the latent form during the same 
time period. 
Discussion 
We have found that plasminogen activator inhibitor activity 
is associated with three compartments of endothelial cell cul- 
tures: the cytosol, the membrane-containing particulate frac- 
tion, and the growth substratum. All three fractions showed 
tPA inhibitor activity on reverse fibrin autographs, and im- 
munoblotting analysis and immunoprecipitation studies indi- 
cated that this inhibitor activity was PAl-1 (endothelial cell 
type inhibitor). 
Our observation that the PAl-1 inhibitor is  found in the 
substratum is in agreement with reported studies using hu- 
man lung fibroblasts (18) and fibrosarcoma cells (29). In both 
cases a radioactive band with an apparent Mr of 46,000 was 
shown to contain PAl activity and  PAI-1 antigen and  im- 
munofluorescent studies showed PAl-1 as a smooth, evenly 
distributed protein within the growth substratum.  We have 
observed that PAId is rapidly deposited into the substratum 
of human endothelial cells, preceding its entry into the cul- 
ture medium, and represents a major component of the sub- 
stratum. Most of the inhibitor is released from the substratum 
within  6  h  after deposition,  indicating  that  the  inhibitor 
reaches the medium via the substratum and not directly from 
the cells. It is not apparent from the data whether all of the 
inhibitor released into the medium originates from the sub- 
stratum or whether the endothelial cells secrete PAI-1 in a 
bidirectional manner. The release of  the inhibitor is dependent 
on the presence of the cells, since incubation of substratum 
from which cells have been extracted does not result in a 
significant decline in PAl-1 levels (Levin, E. G., unpublished 
Levin and Santell PAI-1 and Endothelial  Cell Substratum  2547 observations). The rapid deposition of  the inhibitor may play 
a role in protecting other matrix proteins from proteolysis by 
plasminogen activator-generated proteases. 
Incubation of isolated substratum with tPA  results in a 
depletion of the 46,000-Mr band and the appearance of two 
major inhibitor-containing bands of U0,000 and 44,000 Mr. 
After a 5-min incubation the two new inhibitor-containing 
bands are associated mostly with the substratum but also ap- 
pear in the supernatant. After 10 min more both bands are 
found exclusively in the  supernatant,  suggesting that tPA 
modifies the inhibitor on the surface of the growth substra- 
tum and is followed by dissociation. It is possible that cleav- 
age of the reactive center of PAId by tPA reduces the affinity 
of the inhibitor for the component of  the substratum to which 
it binds. In addition to modifying  the inhibitor, incubation of 
the substratum with tPA appeared to reduce the total amount 
of the  [3SS]methionine-labeled  PAId that could be recov- 
ered on SDS gels (Fig. 4). Most of this apparent loss could 
be explained by the separation of the COOH-terminal end of 
the inhibitor (residues 347-379),  which contains 30% of the 
methionines (26).  Aside from this, it is not obvious what is 
responsible for the rest of the discrepancy. We do not detect 
any low molecular weight (10,000 or greater) degradation 
products of PAId after tPA treatment on 5-15 % gels, nor do 
we detect a  significant decrease in the total number of 35S 
counts per minute during any step of the experiment, thereby 
eliminating sample loss as the reason. We are now investigat- 
ing whether further degradation of  PAId occurs during treat- 
ment with tPA. 
The  reduction in  apparent  inhibitor relative molecular 
mass and its irreversible inactivation after tPA addition is 
similar to that reported by Nielsen et al. (26) after addition 
oftPA or uPA to soluble SDS-treated PAId. However, in con- 
trast to our observations, no tPA-inhibitor complexes were 
observed and all of the inhibitor was converted to the faster 
migrating species.  Whether the difference in these results 
represents different fractions of the inhibitor, the effect of 
SDS,  or  different intermediate  reaction  products  is  not 
known. 
Incubation of the substratum with elastase had a profound 
effect on the band pattern observed on acrylamide gels. Most 
obvious  was  the disappearance  of the band  representing 
fibronectin and the 46,000-Mr  PAId.  The PAId  was con- 
verted to a form that was identical in mobility on SDS gels 
to that produced by tPA, and, like the latter, had no activity. 
Thus elastase, like tPA, has multiple effects on the substra- 
tum-associated inhibitor: modification to a faster migrating 
protein, irreversible inactivation, and release. Interestingly, 
attempts  to  modify the  latent form of the  inhibitor with 
elastase have failed; neither a change in relative molecular 
mass  or  irreversible  inactivation are  observed.  Previous 
reports have demonstrated that incubation of elastase with 
~t2-antiplasmin and C1  inactivator (2)  results in a  loss of 
functional inhibitor activity that corresponds to a  limited 
proteolytic cleavage of each inhibitor. Such a cleavage would 
explain the reduction in the PAId relative molecular mass 
seen after elastase addition and could be responsible for its 
release from the matrix. The inactivation of the inhibitor by 
elastase may contribute to the regulation of fibrinolysis and 
may also play a role in vivo in leukocyte invasion of the vas- 
cular wall. 
With regard to the form and stability of the PAId activity 
we  found that  inhibitor  associated  with  the  membrane- 
containing particulate fraction was fully active, although as- 
sociation with the components of this fraction did not inhibit 
its conversion to the latent form, which occurred at a rate 
comparable to the cytosol inhibitor. Therefore, simple as- 
sociation with the insoluble cellular components is not capa- 
ble of stabilizing PAId activity unless it requires an intact 
cell environment. However,  the association of the inhibitor 
with the substratum appeared to stabilize the inhibitor in a 
form that was susceptible to cleavage and complex formation 
with tPA. Because PAId cannot be cleaved by, or form com- 
plexes with tPA in the latent form (26), it is reasonable to 
conclude that the substratum-associated inhibitor is fully ac- 
tive and that even after 6 h of incubation at 37~  no conver- 
sion to the latent form occurs. Thus the inhibitor is stabilized 
by its association with a component of  the substratum. More 
work will be needed to identify  the relationship of  this inhibi- 
tor to the various components of the substratum and the 
mechanism by which conversion is inhibited. 
This research was supported in part by National Institutes of Health grant 
HL30244. 
Received for publication 2 March 1987, and in revised form 18 August 1987. 
References 
1. Andreasen, P. A., L. S. Nielsen, P. Kristensen, J. Gr~ndahl-Hansen, L. 
Skriver, and K. DanO. 1986. Plasminogen  activator inhibitor from human 
fibrosarcoma  cells binds  urokina~-type  plasminogen  activator, but not its 
proenzyme. J.  Biol. (Taem. 261:7644-7651. 
2. Brower, M. S., and P. C. Harpet. 1982. Proteolytic cleavage and inactiva- 
tion of alpha-2 plasmin inhibitor and C1 inactivator by human polymor- 
phonuclear leukocyte elastase. J. Biol. Ozetr~ 257:9849-9854. 
3. Buroette, W. N. 1981. "Western Blotting~: electrophorctic transfer of pro- 
teins from sodium dodecyl sulfate-polyacrylamide gels to unmodified 
nitrocellulose and radiographic detection with antibody and radioiodi- 
hated protein A. Anal.  Biochem.  112:195-203. 
4. Coleman, P. L., P. A. Barouski, and T. D. Gelehrter.  1982.  The dexa- 
methasone-induced  inhibitor of fibrinolytic  activity in hepatoma cells. J. 
Biol.  Chem. 257:4260-.4263. 
5. Colucci, M., J. A. Paramo, and D. Collen. 1985. Generation in plasma of 
a fast-acting inhibitor of plasminogen activator in response to endotoxin 
stimulation. J.  Clin. Invest.  75:818-824. 
6. Dome, A. M., E. Dupuy, and E. Bodevin. 1978.  Production of a fibrino- 
lyric inhibitor by cultured endothelial cells derived from human  umbilical 
vein. Thromb.  Res.  12:377-387. 
7. Eaton, D. L., and J. B. Baker. 1983. Phorbol ester and mitogens stimulate 
human fibroblast secretions of plasma-activatable plasminogen activator 
and protease nexin, an antiactivator/antiplasmin. J.  Cell Biol. 97:323- 
328. 
8. Emeis, J. L, V. W. M. van Hinsbergh, and J. H. Verheijen. 1983. Inhibi- 
tion of tissue type plasminogen activator by conditioned medium from 
cultured human and porcine vascular endothelial cells. Biochem.  BIO- 
phys.  Res. Commun.  110:392-398. 
9. Erickson, L. A., C. M. Hekman, and D. J. Loskutoff. 1985. The primary 
plasminogen-activator inhibitors in endothelial cells, platelets, serum, 
and plasma are immunologically  related. Proc. Natl. Acad. Sci. USA. 82: 
8710-8714. 
10. Erickson, L. A., D. A. Lawrence, and D. J.  Loskutoff. 1984.  Reverse 
fibrin autography: a method to detect and partially  characterize protease 
inhibition al~er sodium dodecyl sulfate-polyacrylamide gel electropho- 
resis. Anal Biochem.  137:454-463. 
11. Herman, K., M. Kurkinen, K. Alitalo, A. Vaheri, S. Johansson, and M. 
Hook. 1979. Isolation of the pericellular matrix of haman fibroblast cul- 
tures. J.  Cell. Biol. 81:83-91. 
12. Hekman, C. M., and D. L  Loska~toff. 1985.  Endothelial cells produce a 
latent inhibitor ofplasminogen  activators that can be activated by denatur- 
ants. J.  Biol. O~em. 260:11581-11587. 
13. Isaacs, J., N. Savion, D. Gospodarowicz, and M. A. Shuman. 1981. Effect 
of cell density on thrombin binding to a specific site on bovine vascular 
endothelial cells. J.  Cell, Biol. 90:670-674. 
14. Johnson, D. A., J. W. Gantsch, J. R. Sportsman, andJ. H. Elder.  1984. 
Improved technique utilizing nonfat dry milk for analysis of proteins and 
nucleic acids transferred to nitrocellulose. Gene. Anal.  Tech. 1:3-8. 
15. Kroithof, E. K., C. Tran-Thang, C. Tran, and F. Eachmann. 1986.  The 
fast-acting inhibitor of tissue-type  plasminogen  activator in plasma is also 
The Journal of Cell Biology, Volume 105,  1987  2548 the  primary  plasma  inhibitor  of  urokinase.  Thromb. Haemostasis. 
55:65-69. 
16. Krnithoff, E. K. O., J. D. Vassalli, W. D. Schleuning, R. J. Mattaliano, 
and F. Bachmann. 1986. Purification  and characterization of a plasmino- 
gen activator inhibitor from the histiocytic lymphoma cell line U-937. J. 
Biol.  Chem. 261:11207-11213. 
17. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly 
of the head of bacteriophage T4. Nature  (Lond.). 277:680--685. 
18. Laiho, M., O.  Saksela, P.  A. Andrea,son,  and J.  Keski-Oja.  1986.  En- 
hanced production and extracellular deposition of the endothelial-type 
plasminogen activator inhibitor in cultured human lung fibroblasts by 
transforming growth factor-beta. J.  Cell. Biol. 103:2403-2410. 
19. Levin, E. G. 1983. Latent tissue plasminogen  activator produced by human 
endothelial cells in culture: evidence for an enzyme-inhibitor complex. 
Proc.  Natl. Acad.  Sci. USA. 80:6804-6808. 
20. Levin, E. G. 1986. Quantitation and properties of the active and latent plas- 
minogen activator  inhibitors  in  cultures of human endothelial  cells. 
Blood.  67:1309-1313. 
21. Levin, E. G., and D. L Loskutoff. 1979. Comparative studies of the fibrino- 
lyric activity of cultured vascular cells. Thromb. Res.  15:869-878. 
22. Levine, J. D., J. M. Harlan, L. A. Harker, M. L. Joseph, and R. B. Counts. 
1982. Thrombin-mediated  release of Factor VIII antigen from human  um- 
bilical  vein endothelial cells in culture. Blood.  60:531-534. 
23. Loskutoff, D. J., K. Roegner, L. A. Erickson, R. R. Schleef, A. Hutten- 
Iocher, P. L. Coleman, and T. D. Gelehrter. 1986. The dexamethasone- 
induced inhibitor of plasminogen activator  in hepatoma cells is anti- 
genically-related to an inhibitor produced by bovine aortic endothelial 
cells. Thromb. Haemostasis.  55:8-11. 
24. Loskutoff, D. J., J. A. van Mourik, L. A. Erickson, and D. A. Lawrence. 
1983. Detection of an unusually stable fibrinolytic  inhibitor produced by 
bovine endothelial cells. Proc.  Natl. Acad.  Sci. USA. 80:6804-6808. 
25. McConahey, P. J., and F. J. Dixon. 1983. Radioiodination of proteins by 
the use of the chloramine-T method. Methods Enzymol.  70:210-213. 
26. Nielsen, L. S., P. A. Andreasen, J. Grendahl-Hansen, L. Skriver, and K. 
Dane. 1986. Plasminogen activators catalyse conversion of inhibitor from 
fibrosarcoma cells to an inactive form with a lower apparent molecular 
mass. FEBS (Fed. Fur. Biochem.  Soc.) Len.  196:269-273. 
27. Parks,  W.  M.,  R.  D.  Gingrich, C.  E.  Dahle,  and J.  C.  Hoak.  1985. 
Identification  and characterization of an endothelial cell-specific  antigen 
with a monoclonal antibody. Blood.  66:816-823. 
28. Plow,  E.  1982.  Leukocyte elasta~ release during blood coagulation. A 
potential mechanism  for activation of the alternative fibrinolytic pathway. 
J.  Clin. Invest.  69:564-572. 
29. Pollanen, J., O. Saksela, E.-M. Salonen, P. Andreasen, L. Nieisqn, K. 
Dan~, and A. Vaheri. 1987. Distinct localization of urokinase-type plas- 
minogen activator and its type I  inhibitor under cultured human fibro- 
blasts and sarcoma cells. J.  Cell. Biol.  104:i085-1096. 
30. Scott, R. W., B. L. Bergman, A. Bajpai, R. T. Hersh, H. Rodriguez, B. N. 
Jones, C. Barreda, S. WaRs, and J. B. Baker.  1985. Protease nexin. Prop- 
erties and a modified purification  procedure. J.  BioL Chem. 260:7029- 
7034. 
31. Sprengers, E. D., H. M. Princen, T. Kooistra, and V. W. van Hinsbergh. 
1985. Inhibition of plasminogen  activators by conditioned medium of hu- 
man hepatocytes and hepatoma cell line Hep (32. J. Lab. Clin. Med. 105: 
751-758. 
32. Sprengers, E.  D., J.  H. Verheijen, V. W. M. van Hinsbcrgh, and J. J. 
Emeis. 1984. Evidence for the presence of two different fibrinolytic  in- 
hibitors in human endothelial cell  conditioned medium. Biochem.  Bio- 
phys.  Acta.  801:163-170. 
33. Stump, D. C., M. Thienpont, and D. Collen. 1986. Urokinase-related pro- 
teins in human urine occur mainly as a  1: ! complex of urokinase with 
an inhibitor. J.  Biol. Chem. 261:1267-1272. 
34. Stump, D. C., M. Thienpont, and D. Collen, 1986. Purification  and charac- 
terization of a novel inhibitor of urokinase from human urine. J.  Biol. 
Chem. 261:12759-12766. 
35. Vassalli, J.-D., J.-M. Dayer, A. Wohlwend, and D. Belin. 1984. Concomi- 
tam secretion of prourokinase and a plasminogen  activator-specific inhib- 
itor  by cultured human monocytes-macrophages. J.  Exp. Med. 159: 
1653-1668. 
36. Wagner, O, F., and B. R. Binder. 1986. Purification  of an active plasmino- 
gen activator inhibitor immunologically related  to the endothelial type 
plasminogen activator inhibitor from the conditioned media of a human 
melanoma cell  line.  J.  Biol. Chem. 261:14471-14481. 
Levin and Santell  PAl-1 and Endothelial  Cell Substratum  2549 